Search
Selected Filters
Displaying 1–10 of 14 news results
-
Foundation and Vision Partners Seek Biomedical Research Support from Congress during COVID-19 Crisis
Delays in Research Impacting Therapy Development
-
The Foundation Fighting Blindness is closely monitoring the COVID-19 situation and its impact on the IRD community.
-
7th Annual Retinal Cell and Gene Therapy Innovation Summit
Please note that the seventh annual Retinal Cell and Gene Therapy Innovation Summit previously scheduled for Friday, May 1st, 2020 in Baltimore, Maryland has been cancelled.
-
VISIONS 2020 Conference registration now open
The Foundation Fighting Blindness VISIONS 2020 conference will be held on June 18-20th at the Hyatt Regency Minneapolis.
-
Foundation Fighting Blindness Investing Nearly $6.5 Million in New Grants
The newly funded research efforts include several therapies that have strong potential to treat a wide range of inherited retinal diseases.
-
Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases
A discussion of strategies concerning the development of autosomal dominant disease therapies at the Translational Research Acceleration Program (TRAP) in November 2013.
-
The Foundation Fighting Blindness and Dr. H. James & Carole Free Collaborate to Combat AMD
Age-related macular degeneration (AMD) is the leading cause of blindness for people over 50 years of age in developed countries.
-
FFB Congratulates RPE65 Gene Therapy Researchers for Champalimaud Award
More than two decades ago, the Foundation Fighting Blindness (FFB) began funding RPE65 gene therapy research that led in late 2017 to LUXTURNA™, the first FDA-approved gene therapy for the eye or an inherited condition. Ultimately, the Foundation provided more than $10 million in funding for the groundbreaking effort.
-
Foundation Fighting Blindness Announces Leadership Succession Plan After 45 Year Legacy
David Brint has been elected Chairman, effective July 1, 2016. Brint succeeds co-founder and current Chairman, Gordon Gund, who will remain a member of the Board of Directors and will continue to be actively involved in the Foundation’s Research Oversight Committee
